𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical experience with decitabine in North American patients with myelodysplastic syndrome

✍ Scribed by Karen W. L. Yee; Elias Jabbour; Hagop M. Kantarjian; Francis J. Giles

Publisher
Springer
Year
2005
Tongue
English
Weight
127 KB
Volume
84
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Survival advantage with decitabine versu
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome : Comparison with historical experience
✍ Hagop M. Kantarjian; Susan O'Brien; Xuelin Huang; Guillermo Garcia-Manero; Farha πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 152 KB

## Abstract ## BACKGROUND Decitabine, a hypomethylating agent, is active and has been approved for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia. Intensive chemotherapy is an accepted form of therapy for patients with higher risk MDS. The comparative efficacy